Or register here
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Scientific Articles

Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non- Sickle dialysis patients

key information

source: British Journal of Haematology

year: 2016

authors: Nielsen L, Canouï-Poitrine F, Jais JP, Dahmane D, Bartolucci P, Bentaarit B, Gellen-Dautremer J, Remy P, Kofman T, Matignon M, Suberbielle C, Jacquelinet C, Wagner-Ballon O, Sahali D, Lang P, Damy T, Galactéros F, Grimbert P, Habibi A, Audard V

summary/abstract:

We performed a retrospective study to assess the changes in clinical, biological and heart echocardiographic parameters in 32 sickle cell disease (SCD) patients beginning haemodialysis. Acute SCD-related complications were similar at 6 months before and 6 months after the initiation of haemodialysis. Median haemoglobin level did not change significantly, but the need for blood transfusions increased (P < 0·001). The 5-year incidence of death was higher in SCD patients (P < 0·0001). The 5-year likelihood of receiving a renal graft was lower in SCD patients (P = 0·022). Our findings suggest that SCD patients have poorer survival and a lower likelihood of receiving a renal graft.

organization: Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Créteil, France; Université Paris-Est-Créteil, (UPEC), DHU (Département Hospitalo-Universitaire) VIC (Virus-Immunity-Cancer), IMRB (Institut Mondor de Recherche Biomédicale), Créteil, France; Groupe Hospitalier Henri Mondor-Albert Chenevier, Service de Santé Publique, Créteil, France; UPEC, DHU A-TVB (Aging-Thorax-Vessels-Blood), IMRB, EA 4393 CEpiA (Clinical Epidemiology And Ageing Unit), Créteil, France; Université Paris Descartes; Hôpital Necker Enfants Malades, Biostatistics & Ile de France REIN Registry Epidemiologic Units, Paris, France; Centre de Référence des Syndromes Drépanocytaires Majeurs, Groupe Hospitalier Henri Mondor-Albert Chenevier, Créteil, France; Laboratoire Régional d'Histocompatibilité, Hôpital Saint-Louis, Paris, France; Direction Générale Médicale et Scientifique, Agence de la Biomédecine, Saint Denis, France; Centre de Recherches en Épidémiologie et Santé des Populations, Villejuif, France; Groupe de Recherche Clinique (GRC) Amyloid Research Insitute, Créteil, France

DOI: 10.1111/bjh.14040

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

© 2026 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close